Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Purchases 23,400 Shares

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler bought 23,400 shares of the stock in a transaction on Monday, August 14th. The shares were bought at an average price of $21.35 per share, for a total transaction of $499,590.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) traded down 0.67% during trading on Wednesday, hitting $22.25. 159,325 shares of the company traded hands. The stock’s market cap is $1.23 billion. The firm has a 50 day moving average price of $26.51 and a 200-day moving average price of $25.80. Accelerate Diagnostics, Inc. has a one year low of $19.20 and a one year high of $30.45.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.01. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.40 million. Analysts predict that Accelerate Diagnostics, Inc. will post ($1.20) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Purchases 23,400 Shares” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2824477/accelerate-diagnostics-inc-axdx-director-jack-w-schuler-purchases-23400-shares.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Credit Agricole S A increased its position in shares of Accelerate Diagnostics by 73.8% in the first quarter. Credit Agricole S A now owns 115,590 shares of the medical research company’s stock worth $2,798,000 after buying an additional 49,100 shares during the last quarter. American International Group Inc. increased its position in shares of Accelerate Diagnostics by 7.1% in the first quarter. American International Group Inc. now owns 14,187 shares of the medical research company’s stock worth $343,000 after buying an additional 939 shares during the last quarter. Blair William & Co. IL increased its position in shares of Accelerate Diagnostics by 7.3% in the first quarter. Blair William & Co. IL now owns 684,207 shares of the medical research company’s stock worth $17,293,000 after buying an additional 46,517 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Accelerate Diagnostics by 16.8% in the first quarter. SG Americas Securities LLC now owns 5,885 shares of the medical research company’s stock worth $142,000 after buying an additional 846 shares during the last quarter. Finally, Stifel Financial Corp bought a new position in shares of Accelerate Diagnostics during the first quarter worth approximately $274,000. 38.65% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently commented on AXDX. ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub upgraded shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $32.00 price target (up from $30.00) on shares of Accelerate Diagnostics in a research report on Monday, June 5th. BTIG Research reiterated a “buy” rating and issued a $34.00 price target on shares of Accelerate Diagnostics in a research report on Wednesday, May 17th. Finally, Zacks Investment Research upgraded shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Monday, May 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. Accelerate Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $33.00.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.